Abstract: The level of serum AMH has been used as an indicator of ovarian reserve and ART outcome. The relationship between AMH and polycystic ovary syndrome (PCOS) has also attracted more and more attention. The ovarian reserve of PCOS patients is different from that of non-PCOS patients of the same age, and the actual age is not the same as the ovarian fertility age in PCOS patients. The mean fertility age of PCOS patients is actually postponed, and the ovarian reserve is better than that of non-PCOS patients of the same age. PCOS patients have their own characteristics of the expression and change of AMH. AMH is abnormally increased in PCOS patients, and the decline of AMH with age is faster than that in non-PCOS patients. There is a strong positive correlation between AMH level and AFC or the follicle number of controlled ovarian stimulation (COS) in PCOS patients. However, there is a controversy correlation between AMH level and IVF-ET pregnancy outcome in PCOS patients. The diagnostic efficacy of AMH for PCOS is good. Because the increase of AMH is related to the specific phenotype and ethnic difference of PCOS patients, the cutoff value of AMH fluctuates widely. Understandably, there is not a unified conclusion on this cutoff value at present.

Key words: Anti-Mullerian hormone, Polycystic ovary syndrome, Ovary, Superovulation